Business Context and Reporting Period
This Form 8-K, dated February 28, 2023, is filed by NioCorp Developments Ltd. ("NioCorp") to disclose financial information related to its proposed business combination with GX Acquisition Corp. II ("GXII"). Under the Business Combination Agreement signed on September 25, 2022, GXII will become a subsidiary of NioCorp. The filing provides audited financial statements for GXII for the years ended December 31, 2022 and 2021, and unaudited pro forma combined financial statements for NioCorp giving effect to the transaction.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Instead, it references the inclusion of the following documents as exhibits containing the detailed data:
- Exhibit 99.1: Audited consolidated balance sheets, statements of operations, changes in stockholders' deficit, and cash flows for GXII for the years ended December 31, 2022 and 2021.
- Exhibit 99.2: Unaudited pro forma condensed combined balance sheet as of December 31, 2022, and statements of operations for the six months ended December 31, 2022, and the year ended June 30, 2022.
The pro forma financial information is presented for informational purposes only and does not represent actual results of operations or project future results.
Material Changes and Transaction Details
The primary material event is the proposed merger between NioCorp and GXII. Key aspects include:
- Transaction Structure: GXII will become a subsidiary of NioCorp.
- Financing: The transaction relies on the consummation of a convertible debenture transaction and a stand-by equity purchase facility with Yorkville Advisors Global, LP ("Yorkville").
- Capital Availability: The amount of cash available to the combined company depends on redemptions by GXII public shareholders.
- Listing: NioCorp expects its common shares to be listed on the Nasdaq Stock Market following the closing.
Outlook, Risks, and Contingencies
Management commentary and forward-looking statements highlight significant uncertainties regarding the transaction and NioCorp's future operations:
- Transaction Risks: The deal may fail to close due to lack of shareholder or regulatory approval, failure to secure financing from Yorkville, or excessive redemptions by GXII shareholders reducing available cash.
- Operational Risks: NioCorp faces risks related to its limited operating history, history of losses, and the need for significant additional capital to complete the Elk Creek Niobium/Scandium/Titanium project.
- Project Specifics: Risks include cost overruns, supply chain issues, inflation, and the speculative nature of mineral exploration and development.
- Going Concern: The filing explicitly notes the risk regarding NioCorp's ability to operate as a going concern.
Investor Verification Checklist
- Review the Joint Proxy Statement/Prospectus: Investors are urged to read the definitive joint proxy statement/prospectus filed on Form S-4 for complete details on the transaction terms.
- Examine Exhibit 99.1 and 99.2: Verify the specific financial health of GXII and the pro forma impact on NioCorp by reviewing the attached financial statements.
- Assess Financing Contingencies: Confirm the status of the convertible debenture and stand-by equity purchase facility with Yorkville, as the transaction is contingent upon these.
- Monitor Redemption Rates: Evaluate the potential impact of GXII shareholder redemptions on the cash available to NioCorp post-transaction.
- Check Regulatory Approvals: Track the progress of required approvals from the SEC, Canadian securities authorities, and shareholders of both entities.